Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This multi-center, observational study will evaluate the clinical practice patterns, efficacy
and safety of RoActemra/Actemra in patients with rheumatoid arthritis who have had an
inadequate response (or were intolerant to) treatment with non-biological DMARDs or with one
biological agent. Data will be collected from each eligible patient initiated on
RoActemra/Actemra treatment by their treating physician according to approved label for 6
months from start of treatment.